Simvastatin improves clinical scores in a rabbit multiple infarct ischemic stroke model: Synergism with a ROCK inhibitor but not the thrombolytic tissue plasminogen activator

Brain Research

Volumn 1344, Issue , 2010, Pages 217-225

  Lapchak, Paul A ^a   Han, Moon Ku ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b Neuroscience Center   (South Korea)

Author keywords

Acute ischemic stroke; Behavior; Clinical; Embolism; Neuroprotection; Toxicity; Translational science

Indexed keywords

FASUDIL; RHO KINASE; SIMVASTATIN; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN EMBOLISM; BRAIN ISCHEMIA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENTIATION; DRUG SAFETY; MALE; MONOTHERAPY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RABBIT; SINGLE DRUG DOSE;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; ANTICHOLESTEREMIC AGENTS; BRAIN INFARCTION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; ENZYME INHIBITORS; FIBRINOLYTIC AGENTS; MALE; RABBITS; RHO-ASSOCIATED KINASES; SIMVASTATIN; STROKE; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

ORYCTOLAGUS CUNICULUS;

EID: 77954083281     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2010.05.035     Document Type: Article

References (82)

1. Amarenco P., Bogousslavsky J., Callahan III A., Goldstein L.B., Hennerici M., Rudolph A.E., Sillesen H., Simunovic L., Szarek M., Welch K.M., and Zivin J.A. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J. Med. 355 (2006) 549-559
2. Bath P.M., Gray L.J., Bath A.J., Buchan A., Miyata T., and Green A.R. Effects of NXY-059 in experimental stroke: an individual animal meta-analysis. Br. J. Pharmacol. 157 (2009) 1157-1171
3. Bays H. Statin safety: an overview and assessment of the data-2005. Am. J. Cardiol. 97 (2006) 6C-26C
4. Bluhmki E., Chamorro A., Davalos A., Machnig T., Sauce C., Wahlgren N., Wardlaw J., and Hacke W. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol. 8 (2009) 1095-1102
5. Broderick J.P., Lu M., Kothari R., Levine S.R., Lyden P.D., Haley E.C., Brott T.G., Grotta J., Tilley B.C., Marler J.R., and Frankel M. Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial. Stroke 31 (2000) 2335-2341
6. Chen J., Zhang C., Jiang H., Li Y., Zhang L., Robin A., Katakowski M., Lu M., and Chopp M. Atorvastatin induction of VEGF and BDNF promotes brain plasticity after stroke in mice. J. Cereb. Blood Flow Metab. 25 (2005) 281-290
7. Chen J., Zacharek A., Li A., Zhang C., Ding J., Roberts C., Lu M., Kapke A., and Chopp M. Vascular endothelial growth factor mediates atorvastatin-induced mammalian achaete-scute homologue-1 gene expression and neuronal differentiation after stroke in retired breeder rats. Neuroscience 141 (2006) 737-744
8. Chmielewski M., Zdrojewski Z., and Rutkowski B. Benefits and menaces related to the use of statins in patients after renal transplantation. Ann. Transplant. 7 (2002) 6-10
9. Cimino M., Balduini W., Carloni S., Gelosa P., Guerrini U., Tremoli E., and Sironi L. Neuroprotective effect of simvastatin in stroke: a comparison between adult and neonatal rat models of cerebral ischemia. Neurotoxicology 26 (2005) 929-933
10. Clark W.M., Albers G.W., Madden K.P., and Hamilton S. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators. Stroke 31 (2000) 811-816
11. Corsini A., Bellosta S., Baetta R., Fumagalli R., Paoletti R., and Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol. Ther. 84 (1999) 413-428
12. Davies S.P., Reddy H., Caivano M., and Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351 (2000) 95-105
13. Delanty N., and Vaughan C.J. Vascular effects of statins in stroke. Stroke 28 (1997) 2315-2320
14. Dolga A.M., Nijholt I.M., Ostroveanu A., Ten Bosch Q., Luiten P.G., and Eisel U.L. Lovastatin induces neuroprotection through tumor necrosis factor receptor 2 signaling pathways. J. Alzheimers Dis. 13 (2008) 111-122
15. Elkind M.S., Sacco R.L., MacArthur R.B., Fink D.J., Peerschke E., Andrews H., Neils G., Stillman J., Corporan T., Leifer D., and Cheung K. The Neuroprotection with Statin Therapy for Acute Recovery Trial (NeuSTART): an adaptive design phase I dose-escalation study of high-dose lovastatin in acute ischemic stroke. Int. J. Stroke 3 (2008) 210-218
16. Elkind M.S., Sacco R.L., Macarthur R.B., Peerschke E., Neils G., Andrews H., Stillman J., Corporan T., Leifer D., Liu R., and Cheung K. High-dose lovastatin for acute ischemic stroke: results of the phase I dose escalation neuroprotection with statin therapy for acute recovery trial (NeuSTART). Cerebrovasc. Dis. 28 (2009) 266-275
17. Endres M. Statins and stroke. J. Cereb. Blood Flow Metab. 25 (2005) 1093-1110
18. Endres M., Laufs U., Huang Z., Nakamura T., Huang P., Moskowitz M.A., and Liao J.K. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 8880-8885
19. Goldstein L.B., Amarenco P., Szarek M., Callahan III A., Hennerici M., Sillesen H., Zivin J.A., and Welch K.M. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology 70 (2008) 2364-2370
20. Halcox J.P., and Deanfield J.E. Beyond the laboratory: clinical implications for statin pleiotropy. Circulation 109 (2004) II42-8
21. Hebert P.R., Gaziano J.M., Chan K.S., and Hennekens C.H. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 278 (1997) 313-321
22. Istvan E. Statin inhibition of HMG-CoA reductase: a 3-dimensional view. Atheroscler. Suppl. 4 (2003) 3-8
23. Jung K.H., Chu K., Jeong S.W., Han S.Y., Lee S.T., Kim J.Y., Kim M., and Roh J.K. HMG-CoA reductase inhibitor, atorvastatin, promotes sensorimotor recovery, suppressing acute inflammatory reaction after experimental intracerebral hemorrhage. Stroke 35 (2004) 1744-1749
24. Karki K., Knight R.A., Han Y., Yang D., Zhang J., Ledbetter K.A., Chopp M., and Seyfried D.M. Simvastatin and atorvastatin improve neurological outcome after experimental intracerebral hemorrhage. Stroke 40 10 (2009) 3384-3389
25. Kashyap M.L. Cholesterol and atherosclerosis: a contemporary perspective. Ann. Acad. Med. Singapore 26 (1997) 517-523
26. Kolovou G.D., Katerina A., Ioannis V., and Cokkinos D.V. Simvastatin: two decades in a circle. Cardiovasc. Ther. 26 (2008) 166-178
27. Kondoh Y., Mizusawa S., Murakami M., Nagata K., Nakamichi H., and Watanabe K. Effects of HA1077, an intracellular calcium antagonist, on neurotransmitter metabolism in rat brain in vivo. Metab. Brain Dis. 6 (1991) 111-124
28. Kramer A.H., Gurka M.J., Nathan B., Dumont A.S., Kassell N.F., and Bleck T.P. Statin use was not associated with less vasospasm or improved outcome after subarachnoid hemorrhage. Neurosurgery 62 (2008) 422-427 discussion 427-30
29. Lansberg M.G., Bluhmki E., and Thijs V.N. Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. Stroke 40 (2009) 2438-2441
30. Lapchak P.A. Development of thrombolytic therapy for stroke: a perspective. Expert Opin. Investig. Drugs 11 (2002) 1623-1632
31. Lapchak P.A. 3alpha-OL-5-beta-Pregnan-20-one hemisuccinate, a steroidal low-affinity NMDA receptor antagonist improves clinical rating scores in a rabbit multiple infarct ischemia model: synergism with tissue plasminogen activator. Exp. Neurol. 197 (2006) 531-537
32. Lapchak P.A. The phenylpropanoid micronutrient chlorogenic acid improves clinical rating scores in rabbits following multiple infarct ischemic strokes: synergism with tissue plasminogen activator. Exp. Neurol. 205 (2007) 407-413
33. Lapchak P.A. Translational stroke research using a rabbit embolic stroke model: a correlative analysis hypothesis for novel therapy development. Transl. Stroke Res. 1 2 (2010) 96-107
34. Lapchak P.A. Efficacy and safety profile of the carotenoid trans sodium crocetinate administered to rabbits following multiple infarct ischemic strokes: a combination therapy study with tissue plasminogen activator. Brain Res. 1309 (2010) 136-145
35. Lapchak P.A., and Araujo D.M. Advances in ischemic stroke treatment: neuroprotective and combination therapies. Expert Opin. Emerg. Drugs 12 (2007) 97-112
36. Lapchak P.A., and De Taboada L. Transcranial near infrared laser treatment (NILT) increases cortical adenosine-5′-triphosphate (ATP) content following embolic strokes in rabbits. Brain Res. 1306 (2010) 100-105
37. Lapchak P.A., and Han M.K. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin reduces thrombolytic-induced intracerebral hemorrhage in embolized rabbits. Brain Res. 1303 (2009) 144-150
38. Lapchak P.A., and Zivin J.A. The lipophilic multifunctional antioxidant edaravone (radicut) improves behavior following embolic strokes in rabbits: a combination therapy study with tissue plasminogen activator. Exp. Neurol. 215 (2009) 95-100
39. Lapchak P.A., Araujo D.M., Song D., Wei J., and Zivin J.A. Neuroprotective effects of the spin trap agent disodium-[(tert- butylimino)methyl]benzene-1, 3-disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator. Stroke 33 (2002) 1411-1415
40. Lapchak P.A., Song D., Wei J., and Zivin J.A. Coadministration of NXY-059 and tenecteplase six hours following embolic strokes in rabbits improves clinical rating scores. Exp. Neurol. 188 (2004) 279-285
41. Lapchak P.A., Kirkeby A.G., Zivin J.A., and Sager T.N. Therapeutic window for nonerythropoietic carbamylated-erythropoietin to improve motor function following multiple infarct ischemic strokes in New Zealand white rabbits. Brain Res. 1238 (2008) 208-214
42. Laufs U., Gertz K., Dirnagl U., Bohm M., Nickenig G., and Endres M. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res. 942 (2002) 23-30
43. Liao J.K. Statins and ischemic stroke. Atheroscler. Suppl. 3 (2002) 21-25
44. Liu X.S., Zhang Z.G., Zhang L., Morris D.C., Kapke A., Lu M., and Chopp M. Atorvastatin downregulates tissue plasminogen activator-aggravated genes mediating coagulation and vascular permeability in single cerebral endothelial cells captured by laser microdissection. J. Cereb. Blood Flow Metab. 26 (2006) 787-796
45. Lyden P., Brott T., Tilley B., Welch K.M., Mascha E.J., Levine S., Haley E.C., Grotta J., and Marler J. Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. Stroke 25 (1994) 2220-2226
46. Lyden P., Lu M., Jackson C., Marler J., Kothari R., Brott T., and Zivin J. Underlying structure of the National Institutes of Health Stroke Scale: results of a factor analysis. NINDS tPA Stroke Trial Investigators. Stroke 30 (1999) 2347-2354
47. Ma T., Zhao Y., Kwak Y.D., Yang Z., Thompson R., Luo Z., Xu H., and Liao F.F. Statin's excitoprotection is mediated by sAPP and the subsequent attenuation of calpain-induced truncation events, likely via rho-ROCK signaling. J. Neurosci. 29 (2009) 11226-11236
48. Maeda A., Yano T., Itoh Y., Kakumori M., Kubota T., Egashira N., and Oishi R. Down-regulation of RhoA is involved in the cytotoxic action of lipophilic statins in HepG2 cells. Atherosclerosis 208 (2010) 112-118
49. Meier N., Nedeltchev K., Brekenfeld C., Galimanis A., Fischer U., Findling O., Remonda L., Schroth G., Mattle H.P., and Arnold M. Prior statin use, intracranial hemorrhage, and outcome after intra-arterial thrombolysis for acute ischemic stroke. Stroke 40 (2009) 1729-1737
50. Montaner J. Treatment with statins in the acute phase of ischemic stroke. Expert Rev. Neurother. 5 (2005) 211-221
51. Moonis M., and Fisher M. HMG CoA reductase inhibitors (statins): use in stroke prevention and outcome after stroke. Expert Rev. Neurother. 4 (2004) 241-247
52. Mueller B.K., Mack H., and Teusch N. Rho kinase, a promising drug target for neurological disorders. Nat. Rev. Drug Discov. 4 (2005) 387-398
53. Naval N.S., Abdelhak T.A., Zeballos P., Urrunaga N., Mirski M.A., and Carhuapoma J.R. Prior statin use reduces mortality in intracerebral hemorrhage. Neurocrit. Care 8 (2008) 6-12
54. Nicholas J.S., Swearingen C.J., Thomas J.C., Rumboldt Z., Tumminello P., and Patel S.J. The effect of statin pretreatment on infarct volume in ischemic stroke. Neuroepidemiology 31 (2008) 48-56
55. Olson M.F. Applications for ROCK kinase inhibition. Curr. Opin. Cell Biol. 20 (2008) 242-248
56. Prinz V., Laufs U., Gertz K., Kronenberg G., Balkaya M., Leithner C., Lindauer U., and Endres M. Intravenous rosuvastatin for acute stroke treatment: an animal study. Stroke 39 (2008) 433-438
57. Relja B., Lehnert M., Seyboth K., Bormann F., Hohn C., Czerny C., Henrich D., and Marzi I. Simvastatin reduces mortality and hepatic injury after hemorrhage/resuscitation in rats. Shock (2009) 10.1097/SHK.0b013e3181cd8d05
58. Rutishauser J. The role of statins in clinical medicine-LDL-cholesterol lowering and beyond. Swiss Med. Wkly 136 (2006) 41-49
59. Schmeer C., Kretz A., and Isenmann S. Statin-mediated protective effects in the central nervous system: general mechanisms and putative role of stress proteins. Restor. Neurol. Neurosci. 24 (2006) 79-95
60. Shabanzadeh A.P., Shuaib A., and Wang C.X. Simvastatin reduced ischemic brain injury and perfusion deficits in an embolic model of stroke. Brain Res. 1042 (2005) 1-5
61. Shimamura M., Sato N., Sata M., Kurinami H., Takeuchi D., Wakayama K., Hayashi T., Iida H., and Morishita R. Delayed postischemic treatment with fluvastatin improved cognitive impairment after stroke in rats. Stroke 38 (2007) 3251-3258
62. Sironi L., Cimino M., Guerrini U., Calvio A.M., Lodetti B., Asdente M., Balduini W., Paoletti R., and Tremoli E. Treatment with statins after induction of focal ischemia in rats reduces the extent of brain damage. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 322-327
63. Sironi L., Gianazza E., Gelosa P., Guerrini U., Nobili E., Gianella A., Cremonesi B., Paoletti R., and Tremoli E. Rosuvastatin, but not simvastatin, provides end-organ protection in stroke-prone rats by antiinflammatory effects. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 598-603
64. Spatz E.S., Canavan M.E., and Desai M.M. From here to JUPITER: identifying new patients for statin therapy using data from the 1999-2004 National Health and Nutrition Examination Survey. Circ. Cardiovasc. Qual. Outcomes 2 (2009) 41-48
65. STAIR. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30 (1999) 2752-2758
66. Sugawara T., Ayer R., Jadhav V., Chen W., Tsubokawa T., and Zhang J.H. Simvastatin attenuation of cerebral vasospasm after subarachnoid hemorrhage in rats via increased phosphorylation of Akt and endothelial nitric oxide synthase. J. Neurosci. Res. 86 (2008) 3635-3643
67. Sugawara T., Jadhav V., Ayer R., and Zhang J. Simvastatin attenuates cerebral vasospasm and improves outcomes by upregulation of PI3K/Akt pathway in a rat model of subarachnoid hemorrhage. Acta Neurochir. Suppl. 102 (2008) 391-394
68. Tikkanen M.J., Holme I., Cater N.B., Szarek M., Faergeman O., Kastelein J.J., Olsson A.G., Larsen M.L., Lindahl C., and Pedersen T.R. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged < 65 versus > or = 65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study). Am. J. Cardiol. 103 (2009) 577-582
69. Toshima Y., Satoh S., Ikegaki I., and Asano T. A new model of cerebral microthrombosis in rats and the neuroprotective effect of a Rho-kinase inhibitor. Stroke 31 (2000) 2245-2250
70. Trinkl A., Vosko M.R., Wunderlich N., Dichgans M., and Hamann G.F. Pravastatin reduces microvascular basal lamina damage following focal cerebral ischemia and reperfusion. Eur. J. Neurosci. 24 (2006) 520-526
71. Uyttenboogaart M., Koch M.W., Koopman K., Vroomen P.C., Luijckx G.J., and De Keyser J. Lipid profile, statin use, and outcome after intravenous thrombolysis for acute ischaemic stroke. J. Neurol. 255 (2008) 875-880
72. van der Most P.J., Dolga A.M., Nijholt I.M., Luiten P.G., and Eisel U.L. Statins: mechanisms of neuroprotection. Prog. Neurobiol. 88 (2009) 64-75
73. Vivancos-Mora J., and Gil-Nunez A.C. Lipids and stroke: the opportunity of lipid-lowering treatment. Cerebrovasc. Dis. 20 Suppl 2 (2005) 53-67
74. Waldman A., and Kritharides L. The pleiotropic effects of HMG-CoA reductase inhibitors: their role in osteoporosis and dementia. Drugs 63 (2003) 139-152
75. Wang S., Lee S.R., Guo S.Z., Kim W.J., Montaner J., Wang X., and Lo E.H. Reduction of tissue plasminogen activator-induced matrix metalloproteinase-9 by simvastatin in astrocytes. Stroke 37 (2006) 1910-1912
76. Waud D.R. On biological assays involving quantal responses. J. Pharmacol. Exp. Theor. 183 (1972) 577-607
77. Werner N., Nickenig G., and Laufs U. Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Res. Cardiol. 97 (2002) 105-116
78. Wu L., Zhao L., Zheng Q., Shang F., Wang X., Wang L., and Lang B. Simvastatin attenuates hypertrophic responses induced by cardiotrophin-1 via JAK-STAT pathway in cultured cardiomyocytes. Mol. Cell. Biochem. 284 (2006) 65-71
79. Zhang L., Zhang Z.G., Ding G.L., Jiang Q., Liu X., Meng H., Hozeska A., Zhang C., Li L., Morris D., Zhang R.L., Lu M., and Chopp M. Multitargeted effects of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogen activator in the rat. Circulation 112 (2005) 3486-3494
80. Zhang L., Zhang Z.G., Liu X.S., Hozeska-Solgot A., and Chopp M. The PI3K/Akt pathway mediates the neuroprotective effect of atorvastatin in extending thrombolytic therapy after embolic stroke in the rat. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 2470-2475
81. Zhang L., Chopp M., Jia L., Cui Y., Lu M., and Zhang Z.G. Atorvastatin extends the therapeutic window for tPA to 6 h after the onset of embolic stroke in rats. J. Cereb. Blood Flow Metab. 29 (2009) 1816-1824
82. Zivin J.A., Fisher M., DeGirolami U., Hemenway C.C., and Stashak J.A. Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science 230 (1985) 1289-1292